Pharma & Biotech Global Week in Review 11 Nov 09 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

EU: Generics producers: Criminal sanctions can stop counterfeit drugs (IP Watch)

Prandin (Repaglinide) – US: Federal Circuit grants stay of preliminary relief pending full appellate review: Novo Nordisk v Caraco (Patently-O)

 
General

Eduardo Pisani of Bristol-Myers Squibb is the new IFPMA Director General (IP Watch)

Is the practice of medicine impeding medical innovation? (BiotechBlog)

‘Most important’ biodiversity access / benefit meeting (IP Watch)

EU: Patentability of gene sequences and Directive 98/44 (JIPLP)

EU: Generics producers: Criminal sanctions can stop counterfeit drugs (IP Watch)

US: Mayo seeks Supreme Court review in Prometheus Labs case (Patent Docs)

US: Follow-on biologics news briefs – No 9: Patient groups back Senate and House Committee FOB legislation; DelawareBio and BIO seek support of Delaware Delegation; CCPM asks Congress to fix FOB provisions; TJU Dean asks Congress to focus on patient safety (Patent Docs)

US: Issues for another day: Software? Medical diagnostics?: Bilski (IP Frontline)

US: Next up: Ariad v Lilly rehearing en banc (Patent Docs)
 
Products

Ablify (Aripiprazole) – US: Otsuka files patent infringement suit against Teva in response to Para IV challenge (Patent Docs)

Boniva (Ibandronic acid) – US: Roche drops two lawsuits in response to Teva cancelling plans to manufacture generic Boniva (The IP Factor)

Copaxone (Glatiramer) – US: Teva files amended complaint against Momenta/Sandoz to include infringement of three Copaxone–related patents (SmartBrief)

Copaxone (Glatiramer) – US: Teva files patent infringement suit against Mylan, Natco following Para IV challenge (Patent Docs) (GenericsWeb)

Enbrel (Etanercept) – US: Mathilda and Terrence Kennedy Institute of Rheumatology Trust files patent infringement suit against Amgen based on its manufacture and sale of Enbrel (Patent Docs)

Fentora (Fentanyl) – US: Cephalon files patent infringement suit against Barr Pharmaceuticals following Para IV challenge (Patent Docs)

GeneChip – US: Illumina files patent infringement suit against Affymetrix over manufacture and sale of certain GeneChip products (Patent Docs)

Lipitor (Atorvastatin) – Generic makers line up to sell copies of Pfizer’s Lipitor (GenericsWeb)

Loestrin, Femcon (Norethindrone, Ethinyl estradiol) – US: Warner Chilcott suit against Lupin dismissed in Maryland, to be heard in Delaware (Patent Docs)

Loprox (Ciclopirox) – US: Medicis files patent infringement suit against Glenmark following Para IV challenge (Patent Docs)

Myfortic7 (Mycophenolate) – US: Novartis files patent infringement suit against Apotex in response to Para IV challenge (Patent Docs)

Nexium (Esomeprazole) – US: Astrazeneca files patent infringement suit against Lupin following Para IV challenge (Patent Docs)

OxyContin (Oxycodone) – US: Apotex and Purdue settle suit over OxyContin (Patent Docs)

Oxytrol (Oxybutynin) – US: Settlement announced in Oxytrol litigation between Watson and Barr (Patent Docs)

PradiMet (Repaglinide) – US: Novo Nordisk files patent infringement suit against Actavis following Para IV challenge (Patent Docs)

Prandin (Repaglinide) – US: Stays pending appeal – Federal Circuit grants stay of preliminary relief pending full appellate review: Novo Nordisk v Caraco (Patently-O)

Rozerem (Ramelteon) – US: Teva sued by Takeda over generic version of Rozerem (The IP Factor) (GenericsWeb)

Taxotere (Docetaxel) – US: Aventis files patent infringement suit against Sandoz following Para IV challenge (Patent Docs)

Thrombin JMI (Coagulation Factor II) – US: King Pharmaceuticals and others sue ZymoGenetics for false advertising, trade mark infringement; obtain three temporary restraining orders: (Seattle Trademark Lawyer)

Travatan (Travoprost) – US: Alcon files patent infringement suit against Apotex following Para IV challenge (Patent Docs)

Treagan (Acetic acid, Antipyrine, Benzocaine, U-polycosanol 410) – US: Deston Therapeutics files patent infringement suit against TriGen, Irisys based on manufacture and sale of Treagan (Patent Docs)

Tricor (Fenofibrate) – Elan files patent infringement suit against Impax in response to Para IV challenge (Patent Docs)

Tricor (Fenofibrate) – US: Abbott files patent infringement suit against Impax following Para IV challenge (Patent Docs)

Ultram (Tramadol) – US: Purdue Pharma files patent infringement suit against Cipher Pharmaceuticals following Para IV challenge (Patent Docs)

Xeloda (Capecitabine) – US: Hoffman-La Roche sues Teva et al in response to Para IV challenge (The IP Factor)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: